Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug2756 | PDS-08 Wiki | 1.00 |
| drug2916 | Placebo Wiki | 0.04 |
Navigate: Correlations HPO
There is one clinical trial.
The 2019-20 coronavirus disease, caused by COVID-19, is an ongoing pandemic.So far, no specific treatment has proven efficacy. Recent case series reported the use of Hyperbaric Oxygen Therapy (HBOT) on 5 severe COVID-19 patients who developed respiratory insufficiency. HBOT mechanisms of tissue oxygenation and anti-inflammatory effect may explain these findings. The purpose of the current study is the evaluate the efficacy of HBOT in moderate-severe COVID-19 patients in a randomized controlled manner.
Description: Oxygenation index of the lungs calculated PaO2 measured in the blood divided by the inhaled FiO2
Measure: PaO2/FiO2 Time: 5 days after randomizationDescription: Oxygen saturation measured in % by oxygen apparatus
Measure: SpO2 Time: 5 days after randomizationDescription: Early Warning Score (NEWS) calculated by the patient's vitals and condition
Measure: NEWS Score Time: 5 days after randomizationDescription: blood CRP level
Measure: Inflammation level -CRP Time: 5 days after randomizationDescription: white blood cells number
Measure: white blood cells number Time: 5 days after randomizationDescription: blood IL1 level
Measure: Cytokines - IL1 Time: 5 days after randomizationDescription: blood IL2 level
Measure: Cytokines - IL2 Time: 5 days after randomizationDescription: blood IL6 level
Measure: Cytokines - IL6 Time: 5 days after randomizationDescription: blood IL10 level
Measure: Cytokines - IL10 Time: 5 days after randomizationDescription: blood TNFalpha level
Measure: Cytokines - TNFalpha Time: 5 days after randomizationDescription: blood procalcitonin level
Measure: Inflammation level - procalcitonin Time: 5 days after randomizationDescription: blood ferritin level
Measure: Inflammation level - ferritin Time: 5 days after randomizationDescription: Patient's reported symptoms including cough, dyspnea, etc.
Measure: Symptoms level Time: 5 days after randomizationDescription: number of patients who developed SARS-CoV-2 IgM antibodies
Measure: Number of patients with IgM seroconversion Time: 5 days after randomizationDescription: number of patients who developed SARS-CoV-2 IgG antibodies
Measure: Number of patients with IgG seroconversion Time: 5 days after randomizationDescription: Pulmonary function tests performed bedside
Measure: FEV1/FVC Time: 5 days after randomizationDescription: The measured time the patient suffered symptoms until complete recovery
Measure: Time to symptoms recovery Time: Within 30 daysDescription: The number of patients who required invasive ventilation during the trial
Measure: Number of patients who required invasive ventilation Time: Within 30 daysDescription: The measured time until the patient had two negative SARS-CoV-2 PCR
Measure: Time to negative virus PCR Time: Within 30 daysDescription: The number of patients who died
Measure: Mortality rate Time: Within 30 daysDescription: The number of adverse events in each arm
Measure: Number of barotrauma events (safety) Time: 5 days after randomizationAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports